Literature DB >> 10634224

Probiotics and inflammatory bowel diseases.

M Schultz1, R B Sartor.   

Abstract

The pathogenesis of inflammatory bowel diseases remains elusive. However, the resident luminal bacteria seem to be an important factor in their development and chronicity. There is evidence to suggest that inflammatory bowel diseases may represent an aggressive immunological response to the resident luminal flora, rather than an alteration in the normal flora. In prior research, probiotic bacteria were effective in managing certain acute diarrheal diseases, and investigators reported that certain Lactobacilli strains seem to have protective immunomodulating and bowel flora manipulating properties. We report the results of recent studies with probiotics in animal models, in which promising effects for the treatment of chronic inflammatory bowel disease, pouchitis, and ulcerative colitis were observed. Future research may clarify a precise role for probiotic bacteria in managing chronic inflammatory bowel diseases.

Entities:  

Mesh:

Year:  2000        PMID: 10634224     DOI: 10.1016/s0002-9270(99)00812-6

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  30 in total

1.  Probiotics and functional foods in gastrointestinal disorders.

Authors:  M H Floch; J Hong-Curtiss
Journal:  Curr Gastroenterol Rep       Date:  2001-08

Review 2.  Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence.

Authors:  J P Achkar; B Shen
Journal:  Curr Gastroenterol Rep       Date:  2001-12

3.  Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice.

Authors:  B Sheil; J MacSharry; L O'Callaghan; A O'Riordan; A Waters; J Morgan; J K Collins; L O'Mahony; F Shanahan
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 4.  Intestinal microflora as a therapeutic target in inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Atsushi Toyonaga; Michio Sata
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

Review 5.  Immunoregulatory Effects of Tolerogenic Probiotics in Multiple Sclerosis.

Authors:  Hadi Atabati; Esmaeil Yazdanpanah; Hamed Mortazavi; Saeed Gharibian Bajestani; Amir Raoofi; Seyed-Alireza Esmaeili; Azad Khaledi; Ehsan Saburi; Jalil Tavakol Afshari; Thozhukat Sathyapalan; Abbas Shapouri Moghaddam; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Effect of bacterial chemotactic peptides on intestinal inflammation in animal models of acute and chronic "relapsed" colitis.

Authors:  Gerardo A Hernández; Melanie R Valentín; Caroline B Appleyard
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

Review 7.  Proposed model: mechanisms of immunomodulation induced by probiotic bacteria.

Authors:  C Maldonado Galdeano; A de Moreno de LeBlanc; G Vinderola; M E Bibas Bonet; G Perdigón
Journal:  Clin Vaccine Immunol       Date:  2007-03-14

8.  Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats.

Authors:  T Kamiya; L Wang; P Forsythe; G Goettsche; Y Mao; Y Wang; G Tougas; J Bienenstock
Journal:  Gut       Date:  2005-12-16       Impact factor: 23.059

9.  Short-chain fructooligosaccharides, in spite of being fermented in the upper part of the large intestine, have anti-inflammatory activity in the TNBS model of colitis.

Authors:  Federico Lara-Villoslada; Oscar de Haro; Desire Camuesco; Mónica Comalada; Javier Velasco; Antonio Zarzuelo; Jordi Xaus; Julio Galvez
Journal:  Eur J Nutr       Date:  2006-07-26       Impact factor: 5.614

Review 10.  Probiotics and medical nutrition therapy.

Authors:  Amy C Brown; Ana Valiere
Journal:  Nutr Clin Care       Date:  2004 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.